dc.contributor
Institut Català de la Salut
dc.contributor
[Neal JW] Division of Oncology, Stanford Cancer Institute, Palo Alto, California. [Santoro A] Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Rozzano, Milan, Italy. [Gonzalez-Cao M] Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain. [Lim FL] Barts Health NHS Trust, St Bartholomew’s Hospital, London, United Kingdom. [Fang B] Astera Cancer Care, East Brunswick, New Jersey. [Gentzler RD] Division of Hematology Oncology, University of Virginia Cancer Center, Charlottesville, Virginia. [Felip E] Medical Oncology Service, Vall d’Hebron Institute of Oncology (VIHO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Neal, Joel
dc.contributor.author
Lim, Farah Louise
dc.contributor.author
Fang, Bruno
dc.contributor.author
Torres Lozada, Patricia
dc.contributor.author
Santoro, Armando
dc.contributor.author
Gonzalez-Cao, Maria
dc.contributor.author
FELIP, ENRIQUETA
dc.date.accessioned
2025-10-25T05:39:11Z
dc.date.available
2025-10-25T05:39:11Z
dc.date.issued
2024-10-31T12:31:25Z
dc.date.issued
2024-10-31T12:31:25Z
dc.date.issued
2024-03-20
dc.identifier
Neal JW, Santoro A, Gonzalez-Cao M, Lim FL, Fang B, Gentzler RD, et al. Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clin Res Reports. 2024 Mar 20;5(10):100666.
dc.identifier
https://hdl.handle.net/11351/12168
dc.identifier
10.1016/j.jtocrr.2024.100666
dc.identifier
001332455000001
dc.identifier.uri
http://hdl.handle.net/11351/12168
dc.description.abstract
Cabozantinib; Immunotherapy; Non-small cell lung cancer
dc.description.abstract
Cabozantinib; Inmunoterapia; Cáncer de pulmón de células no pequeñas
dc.description.abstract
Cabozantinib; Immunoteràpia; Càncer de pulmó de cèl·lules no petites
dc.description.abstract
Abstract
Introduction
We evaluated efficacy and safety of cabozantinib plus atezolizumab or cabozantinib alone in advanced NSCLC previously treated with an immune checkpoint inhibitor (ICI).
Methods
COSMIC-021 (NCT03170960) is a phase 1b, multicenter study in advanced solid tumors. This analysis included patients with stage IV non-squamous NSCLC without actionable genomic aberrations in EGFR, ALK, ROS1, or BRAF-V600E who progressed on one prior ICI and less than or equal to two prior lines of systemic anticancer therapy. Patients received cabozantinib 40 mg orally/day plus atezolizumab 1200 mg intravenously every three weeks (combination cohort) or cabozantinib 60 mg orally/day (single-agent cabozantinib cohort). Primary end point of the combination cohort was objective response rate per Response Evaluation Criteria in Solid Tumors v1.1 by investigator. Outcomes in the single-agent cabozantinib cohort were exploratory.
Results
Eighty-one patients assigned to combination therapy and 31 assigned to single-agent cabozantinib received greater than or equal to one dose of study treatment. Median (range) follow-up was 26.1 months (12.1–44.2) and 22.4 months (1.5–29.0), respectively. Objective response rate was 20% (95% confidence interval: 11.7%–30.1%) in combination cohort and 6% (95% confidence interval: 0.8%–21.4%) in single-agent cabozantinib cohort. Treatment-related adverse events (TRAEs) occurred in 86% of patients in the combination cohort and 90% in the single-agent cabozantinib cohort; grade 3/4 TRAEs were 44% and 48%, respectively. There were two grade 5 TRAEs: pneumonitis (n = 1, combination) and gastric ulcer hemorrhage (n = 1, single-agent). Neither PD-L1 expression in tumor cells nor tumor mutation burden correlated with outcomes.
Conclusions
Cabozantinib plus atezolizumab demonstrated modest clinical activity and manageable toxicity in advanced NSCLC after progression on prior ICI.
dc.format
application/pdf
dc.relation
JTO Clinical and Research Reports;5(10)
dc.relation
https://doi.org/10.1016/j.jtocrr.2024.100666
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Quimioteràpia combinada
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
Pulmons - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.title
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
